Cancer Research UCC Ireland Breakthrough Cancer Research SNMMI Cork University Hospitals Roisin Connolly UCC Cancer Trials Group UCC Research UCC Medicine & Health @UCC Delighted to receive this award and to collaborate with Johns Hopkins Kimmel Cancer Center JHBreastGynResearch Translational Breast Cancer Research Consortium. Big thanks to Roisin Connolly! Vered Stearns Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy)

ETHAN - groundbreaking new Translational Breast Cancer Research Consortium trial for male breast cancer led by PI Dr. Pablo Leone. #ASCO24 Learn more at classic.clinicaltrials.gov/ct2/show/NCT05…

Tomorrow #ASCO24 check out Nadine Tung MD present #TBCRC048 olaparib expanded cohorts of gPALB2 and sBRCA MBC, one of the most rewarding studies I’ve managed in the last decade and a testament to the power of investigator-initiated research BIDMC Dana-Farber’s Breast Oncology Center Translational Breast Cancer Research Consortium

TBCRC048 is a collaborative IST led by #DFHCC and was open at 11 academic centers across the US via Translational Breast Cancer Research Consortium - thank you to the incredibly dedicated study teams at each of the sites and, most importantly, the 114 participants, many of whom traveled great distances for the study

#ASCO24 Translational Breast Cancer Research Consortium

As seen today at #ASCO24 - TBCRC026, HER2-E and tumors with increased immune signaling more likely to respond to HER2-directed therapy in ER-/HER2+ breast cancer treated with neoadjuvant HP without chemo. Translational Breast Cancer Research Consortium Maeve Hennessy

Dr. Nadine Tung discusses TBCRC048 at #ASCO24 - olaparib is effective in patients with MBC with inherited PALB2 mutation or tumor acquired BRCA1 or BRCA2 mutation. Benefit in initial trial confirmed in a larger group of patients Translational Breast Cancer Research Consortium OncoAlert

TBCRC049 presented by PI Barbara O’Brien, MD demonstrated symptom and quality of life improvement, intracranial response & extended survival with the HER2Climb regimen for patients with leptomeningeal disease from HER2+ bc. #ASCO24 ASCO

We are grateful for the support of The Breast Cancer Research Foundation & Susan G. Komen. See you soon at #SABCS24!

.Ada Waks presents RCT TBCRC052/MARGOT at #SABCS24 showing margetuximab (TMP) no statistically sig improved pCR rate vs THP for mostly cT2N0 disease though 10% higher numerically. Did not differ by HR status. Both well tolerated regimens Dana-Farber’s Breast Oncology Center

Another great study run by Translational Breast Cancer Research Consortium and lead by my dear colleague Julie Nangia at Dan L Duncan Comprehensive Cancer Center. 042 used Ruxolitinib for 10-20 days b4 surgery to inhibit pSTAT5 pathway in premalig AH/CIS (ductal/lobular). 1ry endpoint is apoptosis by Caspase3 drop pending #SABCS24 #bcsm

Lots of buzz around @theTBCRC 040 PREDICT-DNA trial presented by Dr. Natasha Hunter 🐝 ➰ ➡️ Among HER2+ & TNBC pts receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬 🔸54% ctDNA <100 ppm after NAT 🔸NPV for residual disease 60% #ASCO2025

TBCRC 040 (PREDICT-DNA trial): Dr. Natasha Hunter presents - -HER2+ or TN pts with MRD assay after NAT and pre surgery -in TNBC, ctDNA MRD status distinguished between those with RD who had excellent vs poor prognosis Heather Parsons Translational Breast Cancer Research Consortium Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) Ben Ho Park

@neil_iyengar shares @theTBCRC 054 phase 1 trial of exercise therapy in pts w/ HR+ MBC on ET + CKD4/6i assigned to 1/4 exercise therapy levels: 🔸1 yr PFS 70% in 90 min/wk 🚶‍♀️ 🔸1 yr PFS 91% in 225min/wk ➡️ selected as RP2D🚶‍♀️ #ASCO2025

Dr. Laura Huppert presents trial-in-progress TBCRC-067 ENCORE ASCO. Improving understanding of real world sequential ADC use in breast cancer. #ASCO2025

Our amazing patient advocates at #ASCO2025